Jardiance, known generically as empagliflozin, is a medication widely used to improve glycemic control in adults with type 2 diabetes. As patients and healthcare providers increasingly seek cost-effective options, the question arises: when is Jardiance going generic?
The Current Landscape of Jardiance
Since its approval by the FDA in 2014, Jardiance has gained popularity due to its when is jardiance going generic effectiveness in managing blood sugar levels and reducing cardiovascular risks. However, the high cost of brand-name medications can be a barrier for many patients. This concern is driving interest in when Jardiance will become available in a generic form.
Patent Status
The patent for Jardiance is set to expire in 2024, which opens the door for generic manufacturers to enter the market. Once the patent lapses, several pharmaceutical companies are likely to file for approval to produce their own versions of the drug.
The Impact of Generics on Patients
The availability of a generic version of Jardiance could significantly reduce the medication’s price, making it more accessible for patients. Generics typically cost less than their branded counterparts while providing the same therapeutic benefits, leading to improved adherence among patients who might otherwise struggle with medication costs.
What to Expect After Generic Release
Once Jardiance goes generic, patients should keep an eye on potential changes in insurance coverage and formulary inclusions. Pharmacists may also provide insights on switching to a generic version if available. It’s essential for patients to discuss any changes with their healthcare provider to ensure continuity of care.
Conclusion
The anticipated release of a generic Jardiance is expected to happen after its patent expiration in 2024. This development could bring substantial relief to many individuals managing diabetes. Staying informed about these changes will help patients make better decisions regarding their treatment options.
For more information on diabetes management and medication options, visit the American Diabetes Association.
